The European Commission, in accordance with the opinion from the European Medicines Agency (EMA), has granted orphan medicinal product designation to Sweden-based Medivir AB (Nasdaq Stockholm: MVIR) for its MIV-818 intended for the treatment of patients with hepatocellular carcinoma, it was reported on Friday.
The product is a pro-drug aimed at selectively treating liver cancer cells and decreasing side effects. It is claimed to be the first liver-targeted, orally administered drug for patients with hepatocellular carcinoma.
Companies that receive Orphan Medicinal Product designation are provided with certain regulatory and financial incentives that include protocol assistance, EU centralised authorisation procedure, decreased regulatory fees and a potential for a 10-year market exclusivity in the European Union to produce and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories